Transcription of JCOG1109 - トップページ：日本臨床腫瘍研究 ...
1 Japan Clinical Oncology Group .. 29-A-3. JCOG . 17ck0106188h0003.. JCOG1109 . IB/II/III T4 CF / DCF /. CF-RT III ver. A randomized controlled phase III comparing CF versus DCF versus CF-RT. as neoadjuvant treatment for locally advanced esophageal cancer RCT of Neoadjuvant therapy for Esophageal cancer by Triple arm NExT study .. / .. 104-0045 5-1-1. 9 17 JCOG PC1109 . 2012 11 1 JCOG . 2013 10 11 ver. JCOG 10 21 . 2014 6 2 ver. JCOG 6 5 . 2015 6 8 ver. JCOG 6 9 . 2017 11 2 ver. JCOG 11 9 . JCOG 1109 ver. 0.. cStage IB/II/III T4 5-FU CDDP CF . 3 5-FU CDDP Docetaxel DCF 5-FU CDDP . Gy CF-RT III . Primary endpoint . Secondary endpoints .. 1) .. 2) UICC-TNM 7 . EMR Te . EMR .. 3) TNM UICC-TNM 7 cStage IB II T4 III . 4) 20 75 . 5) Performance status PS ECOG 0 1 PS . 6) . 7) . EMR/ESD pT1a-LPM M2 . EMR/ESD pT1a-MM M3 . 8) . 5 . 9) 14 2 . 4,000 /mm3 12,000 /mm3. 2/114. JCOG 1109 ver. 10 104 /mm3.
2 G/dL 14 . mg/dL. AST GOT 100 IU/L. ALT GPT 100 IU/L. mg/dL. SpO2 95%. Ccr 60 mL/min * Cockcroft-Gault . Ccr= 140 kg / 72 mg/dL . Ccr= 140 kg / 72 mg/dL . 10) R0 .. 11) .. A CF : B DCF : C CF-RT .. 600 200 . 5 3 .. ver.. 5 3 1 .. 3/114. JCOG 1109 ver.. CRF JCOG . JCOG . 4/114.
